Cargando…

Therapy‐related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor

BACKGROUND: Therapy‐related leukemia is a well‐recognized clinical syndrome. Peptide receptor radionuclide therapy (PRRT) is a modern therapeutic approach using radionuclide combined with somatostatin analog peptide for inoperable or metastatic neuroendocrine tumors. AIMS: Hematologic toxicities inc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kucukyurt, Selin, Yagiz Ozogul, Yeliz, Ercaliskan, Abdulkadir, Kabasakal, Levent, Eskazan, Ahmet Emre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941585/ https://www.ncbi.nlm.nih.gov/pubmed/32896091 http://dx.doi.org/10.1002/cnr2.1282

Ejemplares similares

Impact of the COVID-19 pandemic on the regular follow-up and outcomes of patients with chronic myeloid leukemia in chronic-phase
por: Yılmaz, Umut, et al.
Publicado: (2022)

Ponatinib both as an effective bridge to allogeneic hematopoietic stem cell transplantation and as posttransplant maintenance therapy in a chronic myeloid leukemia patient with myeloid blast crisis
por: Küçükyurt, Selin, et al.
Publicado: (2023)

New kid on the block: C-reactive protein-to-albumin ratio as a new prognostic marker for chronic lymphocytic leukemia: Comment on “C-reactive protein-to-albumin ratio is an independent poor prognostic factor in newly diagnosed chronic lymphocytic leukaemia: A clinical analysis of 322 cases”
por: Küçükyurt, Selin, et al.
Publicado: (2021)

Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes
por: Kucukyurt, Selin, et al.
Publicado: (2020)

Successful Management of Ibrutinib-Induced Thrombocytopenia with Eltrombopag in a Patient with Waldenström Macroglobulinemia
por: Erçalışkan, Abdülkadir, et al.
Publicado: (2022)

The Impact of the COVID-19 Pandemic on the Diagnosis and Management of Patients with Classical Hodgkin Lymphoma: A Single-Center Experience
por: Kucukyurt, Selin, et al.
Publicado: (2021)

Diagnosis and Management of Classical Hodgkin Lymphoma During the COVID-19 Pandemic()
por: Küçükyurt, Selin, et al.
Publicado: (2022)

Giant Cell Arteritis with Concomitant Chronic Myelomonocytic Leukemia
por: Öztaş, Mert, et al.
Publicado: (2021)

Asciminib in chronic myeloid leukemia: many questions still remain to be answered
por: Eşkazan, Ahmet Emre
Publicado: (2021)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
por: Tiribelli, Mario, et al.
Publicado: (2019)

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
por: Keskin, Dilek, et al.
Publicado: (2016)

Interstitial Pneumonitis in a Patient with Chronic Myeloid Leukemia
por: Eşkazan, Ahmet Emre, et al.
Publicado: (2013)

Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia
por: Eşkazan, Ahmet Emre, et al.
Publicado: (2013)

Editorial: Advances in the treatment of chronic myeloid leukemia
por: Eşkazan, Ahmet Emre, et al.
Publicado: (2023)

Theranostics: radionuclide imaging and therapy in neuroendocrine tumours
por: Drake, Brent, et al.
Publicado: (2015)

Initial Findings on the Use of [(225)Ac]Ac-DOTATATE Therapy as a Theranostic Application in Patients with Neuroendocrine Tumors
por: Demirci, Emre, et al.
Publicado: (2023)

Diagnostic and Treatment Obstacles in Acute Myeloid Leukemia: Social, Operational, and Financial
por: Genç, Emine Eylem, et al.
Publicado: (2023)

Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours
por: Lim, Lisi Elizabeth, et al.
Publicado: (2020)

Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
por: Elston, Marianne S., et al.
Publicado: (2021)

Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE
por: Prétot, Dominique, et al.
Publicado: (2023)

Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors
por: Yordanova, Anna, et al.
Publicado: (2020)

COVID-19 in Chronic-Phase Chronic Myeloid Leukemia Patients: A Single-Center Survey from Turkey
por: Yılmaz, Umut, et al.
Publicado: (2021)

Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour
por: da Silva, Tiago Nunes, et al.
Publicado: (2018)

Apparent pacemaker dysfunction during peptide receptor radionuclide therapy for neuroendocrine tumor
por: Asbach, Stefan, et al.
Publicado: (2017)

Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights
por: Starr, Jason S, et al.
Publicado: (2020)

Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients
por: Theiler, Deborah, et al.
Publicado: (2021)

Surgery, Liver Directed Therapy and Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumor Liver Metastases
por: Ngongoni, Rejoice, et al.
Publicado: (2022)

Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors
por: Kobayashi, Noritoshi, et al.
Publicado: (2021)

Simultaneous Detection of B-Cell Chronic Lymphocytic Leukemia and Colon Adenocarcinoma in the Same Mesenteric Lymph Node
por: Eşkazan, Ahmet Emre, et al.
Publicado: (2013)

Long-Term Palliative Effect of Stenting in Gastric Outlet Obstruction Due to Transarterial Chemoembolization with Yttrium-90 in a Patient with Metastatic Neuroendocrine Tumor
por: Caglar, Erkan, et al.
Publicado: (2016)

Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)
por: Sowa-Staszczak, Anna, et al.
Publicado: (2011)

Peptide Receptor Radionuclide Therapy
por: Hofland, Johannes, et al.
Publicado: (2022)

SUN-914 Peptide Receptor Radionuclide Therapy for an Inoperable Small Cell Neuroendocrine Tumor in the Philippines
por: Alegria, Rainier Mark Gabriel
Publicado: (2020)

The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future
por: Liberini, Virginia, et al.
Publicado: (2020)

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review
por: Camus, Baptiste, et al.
Publicado: (2021)

Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors
por: Opalińska, Marta, et al.
Publicado: (2021)

Best Practices for the Coordinated Care of Patients With Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy
por: Hendifar, Andrew E., et al.
Publicado: (2022)

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Zaknun, John J., et al.
Publicado: (2013)

Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life
por: Severi, Stefano, et al.
Publicado: (2017)

Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review
por: Huizing, Daphne Merel Valerie, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c6igjvssub97hl7s9svk3oa5lm